Iphase ds8201a

Whakaahuatanga poto:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Nga kiko o te hua

Tags hua

  • Tuhinga torotoro hua hua DS - 8201A, e kiia ana ko Trastuzumab Deruxtecan (T - DXD), he antibody - he rongoa tarukino (ADC) mo te maimoatanga o He2. Ka whakakotahi i te Her2 - Te Tautuhi i te Antibody Monoclonal (rite ki te Trastuzumab) me te tautoko kaha i te Kaitito (Deruxtecan) hei utu cytotoxic. Ko te tarukino te tuku i te haumanu tika ki nga mate pukupuku e whakaatu ana i a Her2, te whakapai ake i te whaihua i te wa e whakawhāitihia ana te kino ki nga pūtau noa.
    • Kāwai:
      Cathepsin
    • Te nama take kaore .:
      015200.02
    • Te rahi o te waeine:
      200ul, 2mg / ml
    • Kōrero:
      N / a
    • Momo:
      N / a
    • Nga tikanga rokiroki me nga waka:
      Rokiroki i - 70 ° C. Ko te huka maroke i tukuna.

  • O mua:
  • Tō muri mai:
  • Kōwhiringa Reo